Advances in the understanding of myeloma bone disease and tumour growth.
about
Notch signaling deregulation in multiple myeloma: A rational molecular targetDasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsThe role of chemoattractant receptors in shaping the tumor microenvironment.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsConsequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.On the antiquity of cancer: evidence for metastatic carcinoma in a young man from ancient Nubia (c. 1200 BC).Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneTargeting bone as a therapy for myeloma.Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growthCCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone diseaseEvolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseNotch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Concise review: Defining and targeting myeloma stem cell-like cells.Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system.Notch signaling drives multiple myeloma induced osteoclastogenesis.Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alterationGrowth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma.Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic StrategyLIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens
P2860
Q26797283-68A19D92-D229-4F92-983B-2336A07FCD96Q28730433-AB661BED-2BA5-4FCC-B18B-A72B9AD954B5Q33993124-2F2A220E-7905-4C89-9B55-3F8F78F91A75Q34038854-47322A17-036E-4872-96F3-A2820D96289CQ34418934-E0672EE4-0FED-4816-8E82-152C64F27CB0Q34448984-7E41AA4D-F712-433D-8C9E-C23A9E0E9671Q34956540-E80108DD-C3D0-451A-B5FB-EDB1FBFFB588Q35123121-E05F3114-D0F3-43B4-B5D5-A4EF81ECBDD7Q35219019-B0EC7606-0328-4EC0-A89F-21B610A49768Q35603128-C1B83104-9E9B-44E1-ADFD-B4B2491887D3Q35834665-E6467F69-9400-4872-AE26-596DBF22CED4Q36092153-039692B7-326E-4908-AF2A-EB513E656221Q36177928-811C3445-9FD4-44BD-9A36-CE6288A75603Q36234799-3470AF0F-CEA6-4122-AFB7-723233345991Q36288116-D89EA8F2-C882-40EF-AC02-D873DE2098B2Q36718300-97924C60-0DD9-4D47-95DB-E999411C232FQ37372102-1008E30E-0243-4E2A-9163-9218EB898411Q37662286-0679C2D0-0C77-4C01-A4EC-D083D58D39A0Q37678085-4230F56A-CE10-4C11-880A-66436DE44FA6Q38073136-1699AF43-AB84-40E9-82DB-E9C9FA04AA12Q38180656-62C677ED-6BE2-46AD-8C31-44FF10C73480Q38765403-172AFE75-4DAE-4C87-98A1-A7C363E9472EQ38953233-5485EE86-008F-4410-B5E5-234A89219886Q39203918-0C282B47-8EEC-46F8-883E-FB5BAB803B4DQ39402922-535EAB4F-1DB5-46A9-AB49-6F0C16A6B29EQ41548439-EC6CBA03-7667-4042-A2EA-A44B098519EEQ42158465-6005CF3D-F454-44FE-AB08-57C47F670F71Q42317482-9F2E9213-5115-4146-B34C-1DA3D975A8C4Q43062860-056930C2-C586-4B11-9057-1FBD92826BD3Q53238656-0E038ED9-DBED-4C0A-BE08-212C9A5DF6BAQ53381589-0B4AD7C2-1EA3-4413-A892-F1BAC0B6767DQ58566593-2E67A4EC-190C-44FD-BCA0-925A787FEF2CQ58572512-F7B927AE-E71A-4BE3-9525-00CDF090BB20
P2860
Advances in the understanding of myeloma bone disease and tumour growth.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Advances in the understanding of myeloma bone disease and tumour growth.
@ast
Advances in the understanding of myeloma bone disease and tumour growth.
@en
type
label
Advances in the understanding of myeloma bone disease and tumour growth.
@ast
Advances in the understanding of myeloma bone disease and tumour growth.
@en
prefLabel
Advances in the understanding of myeloma bone disease and tumour growth.
@ast
Advances in the understanding of myeloma bone disease and tumour growth.
@en
P2860
P1476
Advances in the understanding of myeloma bone disease and tumour growth.
@en
P2860
P304
P356
10.1111/J.1365-2141.2010.08141.X
P407
P577
2010-03-11T00:00:00Z